[exclusive interview] Yushang Weekly's pharmaceutical Witkey can't do big data sales to help him come back from the dead

Shiyuanping, chairman of Chongqing Kangzhou big data Co., Ltd., 10 years ago, shiyuanping transformed from traditional business to medical Internet, built a Witkey model platform, but inadvertently entered the database field, which also won him 10 years of precious time in the medical big data industry Now, big data has become a hot industry in the economic field, and its profit model is constantly upgrading Big data is a hot word, of course, there is no lack of bubbles, and Shi Yuanping's "medicine wisdom net" has begun to make profits in 2016 After learning the Witkey model and taking part in work in 1987, Shi Yuanping was in the pharmacy department of the hospital until he went to the sea in 1996 to sell drugs In those years, although he made money, Shi Yuanping said frankly, "it is not suitable for a pharmaceutical person to engage in sales." This kind of maladjustment comes not only from the relationship between Party A and Party B in drug marketing, but also from patients' complaints about "difficult and expensive medical treatment", and more from their worries about the lack of good drugs in the market In 2006, Shi Yuanping and Li Tianquan, who are engaged in drug research and development, planned to build an Internet platform for medical technology transactions The first mock exam is become fashionable for a time The company has a world-famous pharmaceutical company, Lilly company, which offers a worldwide reward for medical technology solutions This mode has become a popular Witkey mode in China It has been a successful example in Chongqing Starting almost at the same time as zhubajie.com, Shi Yuanping also wants to build a witkey.com in the field of China's Pharmaceutical Technology Trading -- let tens of thousands of domestic pharmaceutical enterprises offer rewards on the platform to release the information of pharmaceutical technology demand, which will naturally lead to purchase and trading This is yaozhi.com, which was launched in 2009 The trading model is down There are four modules in the website: the first part is a forum similar to the post bar, which is a virtual space to increase interaction and traffic; the second part is the Witkey platform "yaozhihui", on which users publish their own medical technology needs and the buyer and the seller realize the transaction; the third part is "yaozhitong", which is an e-mall between pharmaceutical enterprises The fourth part is a database of the pharmaceutical industry Shiyuanping focuses on the platform of pharmaceutical Zhihui, which is engaged in demand release and transaction However, when zhubajie successfully finds investors and its user base and reputation effect expand rapidly, yaozhihui can only rely on shiyuanping's pharmaceutical sales company for "blood transfusion" Shi Yuanping began to reflect on whether the Witkey model can be used in the field of medicine When creating yaozhi.com, Shi Yuanping developed a group of medical databases This project, similar to the library, is purely designed to increase the user's stickiness in the whole platform module design "There must be a reason for others to access your website." For this database, Shi Yuanping didn't care much at first One day in 2012, a consulting phone call from a professor of a Chinese Medicine University attracted his attention "Our databases are free to use, but each person can only export a certain amount of data every day, and this professor's scientific research project needs to export a large number of data, he hopes to buy from us." In the end, the two sides concluded the transaction with 5000 yuan Shi Yuanping realizes that a new business opportunity has emerged After the construction of 2009-2012, the construction of the medical database of Yaozhi network has begun to take shape After 2012, Shi Yuanping increased the depth and breadth of data research, and finally formed a huge medical database, in which almost all the information of global listed drugs are included From 2012, the data of yaozhi.com began to realize revenue, and the annual fee for users has increased from the initial 4800 yuan to the current maximum of 298000 yuan The data sales revenue of yaozhi.com also doubled from 280000 yuan in 2012 This year, the company's revenue has stepped into the ranks of Enterprises above designated size In 2016, big data business upgrading, yaozhi.com has achieved profitability, and the domestic big data industry has also surfaced The business model of big data industry has become richer On the one hand, continue to engage in the research and development and sales of medical data products, on the other hand, upgrade the big data profit model Shi Yuanping said that the world's famous data companies, such as Thomson Reuters and IMS, provide consulting services and solutions for pharmaceutical enterprises, with a single business service fee of up to $1 million With the help of massive basic data, Shi Yuanping has also enriched the development and operation of big data For example, drug R & D faces the problems of high investment, long cycle and high risk The combination of big data and artificial intelligence technology can provide computer-aided research for drug R & D, which can greatly reduce the R & D risk In terms of investment attraction and project implementation, the pharmaceutical park can identify the enterprises and projects introduced through big data The settled enterprises can also obtain technical information, talent introduction and resource allocation through the platform of pharmaceutical intelligence network Centering on the commercial upgrading of the whole big data, the concept of pharmaceutical industry Internet of yaozhi.com is basically clear Dialogue with big data is not just a matter of handling and discovering value Chongqing Morning Post: how can a private enterprise in Chongqing keep ahead in the field of big data? Shi Yuanping: big data of domestic medicine is mainly composed of three business sectors: R & D, production and market Through 10 years of efforts, we have achieved industry leadership in R & D The opportunity for us to do big data is to do it early In addition, we have carried out strategic cooperation with some domestic universities and scientific research institutions, as well as some of our own unique algorithms Upstream news · Chongqing Morning Post: where is the core value of big data? Shi Yuanping: the value of big data doesn't mean that your data is valuable if it's large, but only when you quickly find the data you want from the massive data We do not simply handle the data, but deal with all the information collected as complex as possible, and quickly present the desired results For example, for any drug, the registration, acceptance and approval of its R & D link, the standards and chromatograms of production and inspection link, the instructions of use link, medical insurance catalog, clinical data, market information, policies and regulations, bid winning information, retail price, advertising positioning It's all in one place The traditional way of looking up this kind of information may take three days We only need three minutes Chongqing Morning Post: what's the company's next development plan? Shi Yuanping: we can do a lot of big data application projects For example, at present, we have collected more than 30000 traditional Chinese medicine prescriptions, which has covered almost all the achievements of traditional Chinese medicine in China, as well as the big data analysis model of medical insurance, big data analysis model of drug synthesis, etc In addition to the medical database, we also have databases of pesticides, veterinary drugs, cosmetics, food, health products, medical devices, etc In addition, we have started to lay out the Internet in the pharmaceutical industry this year At present, the domestic capital market has been docking with us Chongqing Morning Post: how do you see the future of this industry? Shi Yuanping: as an emerging field, big data, whether it's the foundation, cloud, software and technical services, or platform operation, the core or finding its own profit model, can play its due value by combining big data with application scenarios and deeply integrating with real enterprises.